Search

Displaying results 3981 - 3990 of 10000 in total
  1. Pathway

    Acylcarnitine (2E,4Z,10Z)-Tetradeca-2,4,10-trienedioylcarnitine

    smpdb.ca/view/SMP0124211
    Metabolic

    (2E,4Z,10Z)-Tetradeca-2,4,10-trienedioylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, (2E,4Z,10Z)-tetradeca-2,4,10-trienedioyl-CoA reacts with L-carnitine to form (2E,4Z,10Z)-tetradeca-2,4,10-trienedioylcarnitine.

    Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 more
  2. Pathway

    Acylcarnitine (2Z,6Z,10Z)-hexadeca-2,6,10-trienedioylcarnitine

    smpdb.ca/view/SMP0124294
    Metabolic

    (2Z,6Z,10Z)-hexadeca-2,6,10-trienedioylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, (2Z,6Z,10Z)-hexadeca-2,6,10-trienedioyl-CoA reacts with L-carnitine to form (2Z,6Z,10Z)-hexadeca-2,6,10-trienedioylcarnitine.

    Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 more
  3. Pathway

    Acylcarnitine (8E,10E,12Z)-octadeca-8,10,12-trienoylcarnitine

    smpdb.ca/view/SMP0124344
    Metabolic

    (8E,10E,12Z)-octadeca-8,10,12-trienoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, (8E,10E,12Z)-octadeca-8,10,12-trienoyl-CoA reacts with L-carnitine to form (8E,10E,12Z)-octadeca-8,10,12-trienoylcarnitine.

    Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 more
  4. Pathway

    Acylcarnitine (7E,10E,13E,16E,19E)-Docosapentaenoylcarnitine

    smpdb.ca/view/SMP0124400
    Metabolic

    (7E,10E,13E,16E,19E)-Docosapentaenoylcarnitine is an acylcarnitine. … In forming an acylcarnitine derivative, (7E,10E,13E,16E,19E)-docosapentaenoyl-CoA reacts with L-carnitine to form (7E,10E,13E,16E,19E)-docosapentaenoylcarnitine.

    Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 more
  5. Drug

    Jaktinib

    go.drugbank.com/drugs/DB17545
    Investigational

    Jaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.). … Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals.

  6. Drug

    Rislenemdaz

    go.drugbank.com/drugs/DB12063
    Investigational

    Mk 0657 has been used in trials studying the treatment of Major Depressive Disorder.

  7. Drug

    Pegcantratinib

    go.drugbank.com/drugs/DB16280
    Investigational

    Pegcantratinib is under investigation in clinical trial NCT03448081 (Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene).

  8. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    [A224449] Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week.

  9. Drug

    Teprasiran

    go.drugbank.com/drugs/DB15064
    Investigational

    Teprasiran is under investigation in clinical trial NCT03510897 (QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery).

  10. Pathway

    Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

    smpdb.ca/view/SMP0029791
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition. It is essential for the optimal function of numerous enzymes that are involved in mitochondrial...

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate